- Home
- NBIX vs CHRW Comparison
NBIX vs CHRW Comparison
Compare NBIX & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- CHRW
- Stock Information
- Founded
- NBIX 1992
- CHRW 1905
- Country
- NBIX United States
- CHRW United States
- Employees
- NBIX N/A
- CHRW N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- CHRW Oil Refining/Marketing
- Sector
- NBIX Health Care
- CHRW Consumer Discretionary
- Exchange
- NBIX Nasdaq
- CHRW Nasdaq
- Market Cap
- NBIX 13.2B
- CHRW 12.2B
- IPO Year
- NBIX 1996
- CHRW 1997
- Fundamental
- Price
- NBIX $128.91
- CHRW $113.86
- Analyst Decision
- NBIX Strong Buy
- CHRW Buy
- Analyst Count
- NBIX 22
- CHRW 20
- Target Price
- NBIX $165.59
- CHRW $114.74
- AVG Volume (30 Days)
- NBIX 935.9K
- CHRW 1.4M
- Earning Date
- NBIX 07-30-2025
- CHRW 07-30-2025
- Dividend Yield
- NBIX N/A
- CHRW 2.18%
- EPS Growth
- NBIX 2.97
- CHRW 58.22
- EPS
- NBIX 3.39
- CHRW 4.40
- Revenue
- NBIX $2,509,900,000.00
- CHRW $17,012,580,000.00
- Revenue This Year
- NBIX $16.12
- CHRW N/A
- Revenue Next Year
- NBIX $15.06
- CHRW $4.47
- P/E Ratio
- NBIX $38.04
- CHRW $25.89
- Revenue Growth
- NBIX 18.42
- CHRW N/A
- 52 Week Low
- NBIX $84.23
- CHRW $84.68
- 52 Week High
- NBIX $157.98
- CHRW $116.16
- Technical
- Relative Strength Index (RSI)
- NBIX 46.34
- CHRW 71.11
- Support Level
- NBIX $130.75
- CHRW $96.89
- Resistance Level
- NBIX $137.44
- CHRW $116.16
- Average True Range (ATR)
- NBIX 3.60
- CHRW 2.77
- MACD
- NBIX -0.71
- CHRW 1.34
- Stochastic Oscillator
- NBIX 33.88
- CHRW 88.44
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.